Prothena Announces Executive Appointments
01 oct. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 sept. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on...
Prothena to Participate in Upcoming September Healthcare Conferences
01 sept. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein...
Prothena Reports Second Quarter 2021 Financial Results and Business Highlights
05 août 2021 16h05 HE
|
Prothena Corporation plc
Net cash provided by operating and investing activities was $36.6 million in the second quarter and $2.9 million for the first six months of 2021; quarter-end cash and restricted cash position of...
Prothena to Report Second Quarter 2021 Financial Results on August 5th
29 juil. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...
Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
26 juil. 2021 09h00 HE
|
Prothena Corporation plc
Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS with...
Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021
20 juil. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, July 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...
Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
12 juil. 2021 07h00 HE
|
Prothena Corporation plc
Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone paymentsNovo...
Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
24 juin 2021 08h30 HE
|
Prothena Corporation plc
Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1PRX005 is an investigational best-in-class...
Prothena to Participate in JMP Securities Life Sciences Conference on June 16
10 juin 2021 14h18 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein...